Research projects funded by ELA in 2014

Written on Tuesday 27 January 2015

The ELA Foundation will fund 13 research projets regarding leukodystrophies in 2014 for a budget of 977 626 Euros: 7 new projects for young investigators for 504 581 Euros, 6 renewed projects for a total of 473 045 Euros. In addition, ELA also funded this year: the biobank project for 200 000 Euros. the MD1003 […]

Read more


Register to the 2015 ELA Families / Scientists Meeting


Written on Thursday 22 January 2015

Each year, the ELA association organizes a meeting for patients and their families. International scientists will attend the meeting where they will present the latest scientific and medical breakthroughs and answer the questions of patients and families. This annual event is a unique opportunity for the patients and their families to gain knowledge and interact […]

Read more...


Launch of the MD1003 trial in adrenomyeloneuropathy in France and Spain


Written on Monday 24 November 2014

We are happy to announce the launch in France and Spain of the clinical trial testing the MD1003 drug developed by MedDay Pharmaceuticals in patients with adrenomyeloneuropathy (AMN). Authorizations for the investigational center in Germany are awaited. The trial, funded by ELA for 800.000 euros, will gather 60 AMN men with no cerebral involvement. Below […]

Read more...


Characteristics of Krabbe disease in adults


Written on Monday 24 November 2014

Krabbe disease is a leukodystrophy where the severe form usually begins in early infancy, during the first year of life, and progresses rapidly. It causes demyelination of the central and peripheral nervous systems. The aim of this study was to describe the clinical, radiological and genetic characteristics of Krabbe disease in adult patients for whom […]

Read more...


Study of cerebral metabolic impairment in metachromatic leukodystrophy


Written on Tuesday 21 October 2014

Metachromatic leukodystrophy (MLD) is a neurodegenerative metabolic disease caused by a deficiency in a protein named arylsulfatase A.¬† The defect leads to the accumulation of sulfatides in the nervous system. The aim of this study was to measure brain metabolic impairment in 4 children suffering from the late infantile form of the disease, with the […]

Read more...


A derivative of vitamin E aids in the repair of myelin in multiple sclerosis


Written on Wednesday 15 October 2014

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that causes demyelination and axonal loss, resulting in a severe neurological handicap. Current treatments of MS are mainly aimed towards neuro-inflammation and have a minor impact on myelin repair in the CNS. A treatment that stimulates remyelination would represent a major advance […]

Read more...


Mesenchymal stromal cell transplant induces re-myelination in a multiple sclerosis model


Written on Monday 29 September 2014

Demyelinating diseases such as leukodystrophies and multiple sclerosis are neurodegenerative diseases characterized by a progressive loss of myelin and cells responsible for its synthesis, the oligodendrocytes. Upon demyelination, the cells giving rise to oligodendrocytes are activated and can migrate towards the injured zone where they change into oligodendrocytes. Unfortunately, when demyelination becomes chronic, the cells […]

Read more...